We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
- Authors
Joensuu, Heikki; Eriksson, Mikael; Sundby Hall, Kirsten; Hartmann, Jörg T; Pink, Daniel; Schütte, Jochen; Ramadori, Giuliano; Hohenberger, Peter; Duyster, Justus; Al-Batran, Salah-Eddin; Schlemmer, Marcus; Bauer, Sebastian; Wardelmann, Eva; Sarlomo-Rikala, Maarit; Nilsson, Bengt; Sihto, Harri; Monge, Odd R; Bono, Petri; Kallio, Raija; Vehtari, Aki; Leinonen, Mika; Alvegård, Thor; Reichardt, Peter
- Abstract
Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared with placebo.
- Publication
JAMA, 2012, Vol 307, Issue 12, p1265
- ISSN
1538-3598
- Publication type
Journal Article
- DOI
10.1001/jama.2012.347